The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Achievement of MDA with deucravacitinib in PsA: Results from a phase II trial
|
Deucravacitinib is a novel TYK2 inhibitor that is approved for the treatment of psoriasis in multiple countries and is currently being investigated in PsA. A phase II, multicenter, double-blind trial (NCT03881059) evaluated the safety and efficacy of deucravacitinib in PsA. Patients were randomized 1:1:1 to deucravacitinib (6 mg or 12 mg) or placebo. A post-hoc analysis of this trial, published in Oxford Rheumatology, evaluated the achievement of MDA components through Week 16. Achievement of MDA is associated with improved outcomes and quality of life in patients with PsA. |
| Key learnings |
| Deucravacitinib was more effective than placebo in achieving MDA after 16 weeks, with 22.9% and 23.9% of patients treated with 6 mg and 12 mg deucravacitinib meeting MDA criteria compared with 7.6% of patients treated with placebo. |
| Deucravacitinib-treated patients showed improvement across MDA components, such as tender/swollen joint counts, patient-reported pain, and skin psoriasis (PASI score). All MDA responders met the tender entheseal points ≤1 criterion; however, 47.3% of patients had already met the criterion at baseline. |
| Improvements in several MDA components, including physical functioning and pain, were evident as early as 4 weeks after treatment initiation, indicating a rapid onset of action. |
| These findings suggest that deucravacitinib could be a viable alternative for patients who cannot achieve adequate disease control with existing PsA therapies, potentially improving both short- and long-term quality of life and function in these patients. |
Abbreviations: MDA, minimal disease activity; PASI, psoriasis area and severity index; PsA, psoriatic arthritis.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
